| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1315 | 2017 |
| Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis KA Papp, A Blauvelt, M Bukhalo, M Gooderham, JG Krueger, JP Lacour, ... New England Journal of Medicine 376 (16), 1551-1560, 2017 | 570 | 2017 |
| Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled … C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz, C Ferrandiz, ... British Journal of Dermatology 173 (6), 1387-1399, 2015 | 529 | 2015 |
| Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial R Bissonnette, KA Papp, Y Poulin, M Gooderham, M Raman, L Mallbris, ... British Journal of Dermatology 175 (5), 902-911, 2016 | 513 | 2016 |
| Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis K Papp, K Gordon, D Thaçi, A Morita, M Gooderham, P Foley, IG Girgis, ... New England Journal of Medicine 379 (14), 1313-1321, 2018 | 420 | 2018 |
| Dupilumab: a review of its use in the treatment of atopic dermatitis MJ Gooderham, HC Hong, P Eshtiaghi, KA Papp Journal of the American Academy of Dermatology 78 (3), S28-S36, 2018 | 355 | 2018 |
| Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) A Menter, KA Papp, M Gooderham, DM Pariser, M Augustin, FA Kerdel, ... Journal of the European Academy of Dermatology and Venereology 30 (7), 1148-1158, 2016 | 279 | 2016 |
| A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of … MJ Gooderham, H Adlercreutz, ST Ojala, K Wähälä, BJ Holub The Journal of nutrition 126 (8), 2000-2006, 1996 | 211 | 1996 |
| The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo … K Reich, M Gooderham, L Green, A Bewley, Z Zhang, I Khanskaya, ... Journal of the european academy of dermatology and venereology 31 (3), 507-517, 2017 | 204 | 2017 |
| Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials MG Lebwohl, KA Papp, LB Marangell, J Koo, A Blauvelt, M Gooderham, ... Journal of the American Academy of Dermatology 78 (1), 81-89. e5, 2018 | 181 | 2018 |
| Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 … P Rich, M Gooderham, H Bachelez, J Goncalves, RM Day, R Chen, ... Journal of the American Academy of Dermatology 74 (1), 134-142, 2016 | 178 | 2016 |
| Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne J Tan, D Thiboutot, G Popp, M Gooderham, C Lynde, J Del Rosso, ... Journal of the American Academy of Dermatology 80 (6), 1691-1699, 2019 | 147 | 2019 |
| Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase … K Papp, H Bachelez, A Costanzo, P Foley, M Gooderham, P Kaur, ... Journal of the American Academy of Dermatology 76 (6), 1093-1102, 2017 | 145 | 2017 |
| Shifting the focus–the primary role of IL‐23 in psoriasis and other inflammatory disorders MJ Gooderham, KA Papp, CW Lynde Journal of the European Academy of Dermatology and Venereology 32 (7), 1111-1119, 2018 | 136 | 2018 |
| Review of atopic dermatitis and topical therapies JN Mayba, MJ Gooderham Journal of Cutaneous Medicine and Surgery 21 (3), 227-236, 2017 | 133 | 2017 |
| Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR) B Strober, M Gooderham, EMGJ de Jong, AB Kimball, RG Langley, ... Journal of the American Academy of Dermatology 78 (1), 70-80, 2018 | 125 | 2018 |
| Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) A Blauvelt, M Gooderham, L Iversen, S Ball, L Zhang, NO Agada, K Reich Journal of the american academy of dermatology 77 (5), 855-862, 2017 | 125 | 2017 |
| Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies KA Papp, B Haraoui, D Kumar, JK Marshall, R Bissonnette, A Bitton, ... Journal of cutaneous medicine and surgery 23 (1), 50-74, 2019 | 123 | 2019 |
| The psychosocial impact of hidradenitis suppurativa M Gooderham, K Papp Journal of the American Academy of Dermatology 73 (5), S19-S22, 2015 | 113 | 2015 |
| A guide to topical vehicle formulations JN Mayba, MJ Gooderham Journal of Cutaneous Medicine and Surgery 22 (2), 207-212, 2018 | 110 | 2018 |
